Enliven Therapeutics, Inc.
Financials
Valuation Metrics
Enliven Therapeutics, Inc.'s Market Cap is $3.62B. At end of 2025 it was $873M. Ranked #1572 of 3,121 in US market (top 50%), #552 of 1,463 on NASDAQ (top 38%), #94 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.62B | US#1,572/3,121 Sec#94/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-106M | US—/3,121 Sec—/266 |
| Total Assets | $910M | US#2,521/3,121 Sec#109/266 |
| Net Assets | $895M | US#1,846/3,121 Sec#75/266 |
| Employees | 67 | US#2,683/3,121 Sec#199/266 |
| Value | ||
| P/B | 4.05x | US#2,049/3,121 Sec#121/266 |
| FCF Yield | -1.85% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -11.83% | US#2,392/3,121 Sec#83/266 |
| ROA | -11.64% | US#2,693/3,121 Sec#105/266 |
| Financial Health | ||
| Debt Ratio | 1.68% | US#15/3,121 Sec#3/266 |
| Total Debt | $2M | US#2,971/3,121 Sec#239/266 |
| FCF | $-67M | US#2,568/3,121 Sec#122/266 |
| Cash | $136M | US#2,020/3,121 Sec#146/266 |
| Current Ratio | 64.07x | US#48/3,121 Sec#4/266 |
| Performance | ||
| 1Y Return | 148.12% | US#93/3,121 Sec#39/266 |
| 1M Return | -16.74% | US#2,873/3,121 Sec#230/266 |
| From 52W High | -20.65% | US#1,462/3,121 Sec#106/266 |
| 1Y MDD | -36.84% | US#1,848/3,121 Sec#127/266 |
| Trading | ||
| Volume | 2,973,653 shares | US#864/3,121 Sec#87/266 |
| Trading Value | $149M | US#850/3,121 Sec#57/266 |
| Per Share | ||
| EPS | $-1.45 | US—/3,121 Sec—/266 |
| BPS | $12.22 | US#1,696/3,121 Sec#61/266 |
Company Info
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.